39th Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 3, 2021 – Friday, November 5, 2021

Location
New York Marriott Marquis
1535 Broadway
New York, NY 10036
Phone: 212-398-1900

Overview

Exciting new breakthroughs and rapid changes continue to occur in the management of solid and hematologic malignancies. Just this past year, practice-changing diagnostic, therapeutic, and supportive care strategies have entered clinical practice, and many more are poised to enter the field. The application of optimized testing approaches, locoregional and systemic therapies, including the use of chemotherapies, targeted therapies, immunotherapies, alone and in combination, along with multimodal strategies, continue to drive improved outcomes across multiple lines of care. Critical knowledge, competence, and performance gaps among practitioners must be addressed to ensure that these approaches are effectively and safely integrated into professional practice.

Each year, the Chemotherapy Foundation Symposium^® (CFS^®), brings together more than 2000 healthcare professionals for 3 days, with the aim of promoting the delivery of evidence-based, state-of-the-art cancer care for both routine and the most challenging clinical scenarios. At the 39th Annual CFS^®, our internationally renowned faculty will provide you with expert insights on the latest developments in cancer therapeutics, offering an unparalleled opportunity to learn how innovative approaches fit into existing treatment paradigms to optimize care and outcomes for your patients with cancer.

Physicians' Education Resource^®’s top priority is ensuring the safety and security of our attendees, faculty, exhibitors, staff, and operational personnel. We are dedicated to remaining informed about the ongoing COVID-19 pandemic at the global and local levels. As we develop the programming for this activity, Physicians' Education Resource^® is working diligently to implement health and safety protocols based on the advice of health experts and the latest guidelines and local regulations to mitigate the risk of exposure to COVID-19 and to optimize health and safety conditions for attendees during the event. Ongoing updates on Physicians' Education Resource^®'s plans related to this event, including education and programming, will continue to be available at https://www.gotoper.com/conferences/chemo/meetings/39th-annual-chemotherapy-foundation-symposium-innovative-cancer-therapy-for-tomorrow. Please note attendance at any public event increases the risk of contracting COVID-19 or other airborne illness, and attendees assume all risk associated with attendance. Any attendees who feel ill, regardless of their symptoms, should not attend this event.

Benefits of Attending

• Learn from 100 experts across 25 tumor types over 3 days. Something for everyone!
• Return in person or attend virtually to network with the top minds in oncology – your choice!
• Gain in-depth updates on hematologic malignancies, including acute and chronic leukemias, multiple myeloma, lymphoma, and MDS/MPNs. Based on your feedback we’ve expanded this session from ½ day to a full-day focused segment at the conference
• Take advantage of a special breakout track in nursing designed to address unique patient management concerns
• Look for an announcement on which world-renowned experts will be giving our 2 keynote lectures 

Target Audience

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists involved in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Determine the most appropriate testing strategies to identify molecular marker and treatment targets while stratifying risk to inform clinical decision-making in cancer management
• Describe key practice-changing clinical trial results that inform appropriate diagnostic and treatment approaches for patients with hematologic malignancies and solid tumors
• Identify evidence-based immunotherapeutic, chemotherapeutic, and targeted treatment strategies to optimize clinical outcomes
• Delineate implementation strategies for multidisciplinary teams to anticipate and proactively manage treatment-related toxicities
• Review practice-changing evidence presented at major conferences, and apply these findings to optimize the care of patients with cancer

Program Co-Chairs

Ajai Chari, MD
Professor of Medicine, Hematology and Medical Oncology
Director of Clinical Research, Multiple Myeloma Program
Associate Director of Clinical Research, Mount Sinai Cancer Clinical Trials Office
Icahn School of Medicine at Mount Sinai
New York, NY

Benjamin P. Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

Tiffany A. Traina, MD
Associate Attending Physician
Vice Chair, Oncology (Manhattan) Dept of Medicine
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
New York, NY

Registration

Registration

Registration fees include breakfast, breaks, reception(s), and e-syllabus materials.

3 Ways to Register

1. Online: Click here.
2. Phone: Please call +1-(888)-949-0045 or +1-(609)-378-3701 (credit cards only).
3. Fax: +1-(609)-257-0705 (credit cards only).

Physicians' Education Resource^®, LLC - CFSC21
2 Clarke Drive
Suite 110
Cranbury, NJ 08512

*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.

**INDUSTRY is defined by PER^® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

For registration assistance, please email info@gotoper.com, or call +1-(888)-949-0045 or +1-(609)-378-3701.

A cancellation fee of 25% will be assessed on refunds requested prior to September 3, 2021 and a 50% fee on refunds requested on September 4, 2021, through October 3, 2021. No refunds will be made after October 3, 2021. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.

In the event of a meeting cancellation, full refunds will be processed within 30 days of the cancellation date.

Physicians' Education Resource^®, LLC (PER^®) fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call +1-(609)-378-3701.

PER^® reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER^® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER^® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER^® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER^®.

Meeting information is accurate at the time of posting.

PER^® complies with the Physician Payments Sunshine Act as part of the Affordable Care Act. Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the Act.